Targeting Triple-Negative Breast Cancer

0

Breast cancer may develop in one part of the body, but it’s not just one disease. In fact, oncologists think of breast cancer as at least three different types of diseases.

Erica Mayer, MD, MPH

Triple-negative breast cancer (TNBC) describes breast cancer cells that do not have estrogen, progesterone, or HER2 receptors. It makes up approximately 15 percent of all breast cancers and is typically more aggressive than the other two types, estrogen receptor-positive breast cancer and HER2-positive breast cancer.

“It may be the smallest group, but TNBC still represents thousands of women with breast cancer, so it is a very important group for us,” says Erica Mayer, MD, MPH, a medical oncologist at Dana-Farber’s Susan F. Smith Center for Women’s Cancers.

The Susan F. Smith Center for Women’s Cancers organized a live webcast with Mayer earlier this year titled, “Targeting Advanced Triple Negative Breast Cancer.” Mayer spoke about the improved chemotherapy options and clinical trials available for TNBC patients.

“TNBC is a very active area of research,” Mayer says. “We have many new, exciting agents in the pipeline.”

To view Mayer’s presentation, visit Dana-Farber’s Slideshare page.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image
Refresh

*

Latest Tweets

Dana-Farber @danafarber
Fighting Women’s Cancers from Within - https://t.co/uFh2VJv9Zd #bcsm #gyncsm https://t.co/XmZ4c3rMgO
Dana-Farber @danafarber
Increase use of the #HPV vaccine "could help avert tens of thousands of cancer cases during young Americans’ lives." https://t.co/lO77z8W4vU
Dana-Farber @danafarber
RT @brenttippen: .@fitbit is proud to work with @DanaFarber Cancer Center to study #breastcancer and the affects of healthy living. https:/…

Make An Appointment

For adults: 877-442-3324

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.